A5069799062- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Head and Neck Surgical Oncology
- Colorectal and Anal Carcinomas
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Traffic and Road Safety
- Salivary Gland Tumors Diagnosis and Treatment
- Alcohol Consumption and Health Effects
- Advanced Radiotherapy Techniques
- Cancer Immunotherapy and Biomarkers
- Thyroid Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cannabis and Cannabinoid Research
- Cancer-related Molecular Pathways
- Statistical Methods in Clinical Trials
- Oral health in cancer treatment
- Meta-analysis and systematic reviews
- Radiopharmaceutical Chemistry and Applications
- Smoking Behavior and Cessation
- Cancer-related gene regulation
- Substance Abuse Treatment and Outcomes
- Esophageal Cancer Research and Treatment
- Health Systems, Economic Evaluations, Quality of Life
NRG Oncology
2019-2025
National Cancer Institute
2024-2025
American College of Radiology
2021-2024
Center for Cancer Research
2024
American College of Financial Services
2023-2024
National Institutes of Health
2024
RTOG Foundation
2022-2023
Stanford University
2021
University of California, San Francisco
2021
University of Puerto Rico-Mayaguez
2014-2019
Reducing radiation treatment dose could improve the quality of life (QOL) patients with good-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma (OPSCC). Whether reduced-dose produces disease control and QOL equivalent to standard chemoradiation is not proven.In this randomized, phase II trial, p16-positive, T1-T2 N1-N2b M0, or T3 N0-N2b M0 OPSCC (7th edition staging) ≤ 10 pack-years smoking received 60 Gy intensity-modulated therapy (IMRT) over 6 weeks concurrent...
PURPOSE Radiotherapy (RT)/cetuximab (C) demonstrated superiority over RT alone for locally advanced squamous head and neck cancer. We tested this in completely resected, intermediate-risk METHODS Patients had cell carcinoma of the (SCCHN) oral cavity, oropharynx, or larynx, with one more risk factors warranting postoperative RT. were randomly assigned 1:1 to intensity-modulated (60-66 Gy) once-per-week C alone. The primary hypothesis was that + would improve overall survival (OS)...
Importance Pathologic complete response (pCR) may be associated with prognosis in patients soft tissue sarcoma (STS). Objective We sought to determine the prognostic significance of pCR on survival outcomes STS for receiving neoadjuvant chemoradiotherapy (CT-RT) (Radiation Therapy Oncology Group [RTOG] 9514) or preoperative image-guided radiotherapy alone (RT, RTOG 0630) and provide a long-term update 0630. Design, Setting, Participants has completed 2 multi-institutional, nonrandomized...
Management of patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) when cisplatin is contraindicated controversial. We aimed to assess whether radiotherapy concurrent adjuvant durvalumab would improve outcomes compared cetuximab.
Objective: The purpose of this study was to determine (a) whether among sober (blood alcohol concentration [BAC] = .00%) drivers, being drug positive increases the drivers' risk killed in a fatal crash; (b) drinking (BAC > and (c) other drugs interact increasing crash risk. Method: We compared BACs for 2006, 2007, 2008 cases drawn from U.S. Fatality Analysis Reporting System (FARS) with control blood data participants 2007 National Roadside Survey. Only FARS drivers states information on 80%...
Abstract Patient-reported outcomes (PROs) are often collected in cancer clinical trials. Data obtained from trials with PROs essential evaluating participant experiences relating to symptoms, financial toxicity, or health-related quality of life. Although most features trial design, implementation, and analyses apply PROs, several considerations unique. In this paper, we focus on specific issues such as selection the tool, timing frequency assessments, data collection methods. We discuss how...
<div>AbstractPurpose:<p><i>NFE2L2/KEAP1/CUL3</i> mutations have been validated for radioresistance in cell-based assays and animal models. However, clinical validation of these biomarkers has challenging because multimodality treatment regimens. This study aims to investigate the association between <i>NFE2L2/KEAP1/CUL3</i> patient outcomes, including local failure, locoregional disease-free survival (DFS), overall survival, using samples from a phase III...
<p>Study schema of NRG/RTOG 9512</p>
<p>Analysis of local failure, local-regional disease-free survival and overall survival</p>